Mydrane (Lidocaine Hydrochloride Monohydrate, Phenylephrine Hydrochloride, Tropicamide)

Lidocaine blocks voltage‑gated sodium channels, producing local nerve blockade and anesthesia. Phenylephrine, an α1‑adrenergic agonist, contracts the dilator pupillae muscle, while tropicamide, an antimuscarinic, relaxes the sphincter pupillae muscle. Together they achieve swift pupil dilation and analgesia within the eye.

The dose of Mydrane is determined by the operating ophthalmologist based on the specific procedure and patient factors. It is administered as a single intracameral injection at the start of surgery; exact volume and concentration are prescribed by the clinician.

Safety data for Mydrane in pregnancy and lactation are limited. Because the product is administered directly into the eye, systemic exposure is minimal, but clinicians should weigh potential risks and benefits and consider alternative options when treating pregnant or nursing patients.

To order Mydrane, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Mydrane combines a local anesthetic (lidocaine) with two mydriatics (phenylephrine and tropicamide) in a single formulation, offering convenience over separate agents. Compared with using lidocaine alone, Mydrane provides both anesthesia and reliable pupil dilation, reducing preparation time and potential dosing errors.

Mydrane should be stored at ambient temperature, protected from light and moisture, and kept in its original sealed container until use. Do not freeze the product, and avoid exposing it to extreme temperatures that could compromise sterility or efficacy.

Mydrane is administered by a trained ophthalmic surgeon as an intracameral injection directly into the anterior chamber of the eye at the beginning of the procedure. The injection is performed under sterile conditions using a calibrated syringe.

Serious risks include severe allergic reactions such as anaphylaxis, sustained high intraocular pressure that may require intervention, persistent mydriasis, corneal ulceration, endophthalmitis, and systemic cardiovascular events like hypertension or arrhythmia if significant systemic absorption occurs.

Mydrane should be avoided in patients with known hypersensitivity to lidocaine, phenylephrine, or tropicamide, those with uncontrolled narrow‑angle glaucoma, severe cardiovascular disease, or any condition where excessive pupil dilation could compromise ocular health.